Maria Sklodowska-Curie National Research Institute of Oncology shared a post on LinkedIn:
“During this year’s edition of the International Cancer Immunotherapy Conference – CICON25 in Utrecht, one of the most important global events devoted to cancer immunotherapy, the team of the Department of Regenerative Medicine at Maria Sklodowska-Curie National Research Institute of Oncology presented a scientific poster on the assessment of markers qualifying patients for the treatment of TILs in ovarian cancer.
The conference, organized in cooperation with leading scientific societies (Cancer Research Institute, Association for Cancer Immunotherapy – CIMT, European Network for Cancer Immunotherapy, American Association for Cancer Research), brings together outstanding scientists, doctors and innovation leaders every year, creating a space for the presentation of the latest discoveries, results of clinical trials and new technologies in immuno-oncology.
Research on the use of tumor-infiltrating lymphocytes (TILs) in ovarian cancer is carried out at NIO-NRI as part of a project funded by Agencja Badań Medycznych, entitled:
‘Research work on the development of cell culture with potential applications in advanced personalized immunotherapy for ovarian cancer in the standard of Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP)’.
‘During the presentation, we presented the results of a retrospective molecular-clinical analysis, which is a key stage of the project, which is to determine the criteria for selecting material from patients. The most important element of the presentation was the presentation of the mechanism of selection of biomarkers that can serve as qualification criteria for future cell therapies using TILs lymphocytes,’ explains Justyna Marynowska, MD, PhD, Head of the Department of Regenerative Medicine at NIO.
The presentation of the results at such a prestigious conference is an important step in the development of our research and proof of the growing importance of the NIO-NRI team on the international arena, as well as a contribution to the development of personalized oncology, in which treatment is selected according to the individual molecular characteristics of the patient’s disease.”
More posts featuring Ovarian Cancer.